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Lysosomal-associated protein transmembrane 4 beta (LAPTM4B) is known as an oncogene associated with many
human malignant tumors. There are two alleles of the gene, LAPTM4B*1 and LAPTM4B*2. Previous studies have
shown that LAPTM4B polymorphism contributes to the risk of many cancers. This case-control study was to
investigate the relationship between LAPTM4B gene polymorphism and susceptibility of malignant melanoma. The
genotypes of LAPTM4B were determined in 617 control subjects and 220 patients with malignant melanoma by
utilizing polymerase chain reaction based on specific primers. The genotypic distribution of LAPTM4B and Hardy–
Weinberg equilibrium were analyzed by χ2 test. Odds ratio and 95% confidence interval was calculated by
unconditional logistic regression. The distributions of LAPTM4B genotypes were significantly different between
melanoma patients (45.9% for *1/1, 46.4% for *1/2 and 7.7 for *2/2) and controls (54.5% for *1/1, 39.9% for *1/2 and
5.7 for *2/2). LAPTM4B *1/2 and LAPTM4B *2/2 had a 1.396-fold and 1.619-fold higher risk for melanoma occurrence
than *1/1, and subjects with LAPTM4B*2 have a 1.308-fold higher risk than LAPTM4B*1 carriers. No association
between LAPTM4B genotypes and gender, age, subtype, Clark level of invasion, Breslow thickness, ulceration, clinical
stage, and C-KIT, BRAF genemutation status was observed. LAPTM4B*2 is associated with the high risk of malignant
melanoma and carrying LAPTM4B *2 may be a susceptible factor to Chinese melanoma patients.
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Melanoma is amalignant tumor ofmelanocytes, with a high potential to
develop metastases. In the last few decades, the incidence of melanoma
has increased substantially worldwide [1,2]. The annual growth rate of
incidence is approximately 3% to 5%. Genetic, phenotypical, and
environmental factors are involved in melanoma developing [3]. The
manifestation and prognosis are significantly different between Asian
and white populations. The subtype of superficial spreading melanoma
is common in white patients, which is clearly associated with sunlight
exposure [4]. Studies have confirmed that mutations of p16 located in
the chromosome 9 or CDKN2A is the main genetic susceptibility of
melanoma [5]. However, the most frequent subtypes of melanoma in
Asian patients are acral lentiginous melanoma (AM) and mucosal
melanoma (MM) [6,7]. The primary lesions were not always exposed to
the ultraviolet, so the specific causative factor for increasing melanoma
incidence in China was still unclear [6].Lysosome-associated protein transmembrane 4 beta (LAPTM4B), is
a new gene first cloned in hepatocellular carcinoma [8]. It was mapped
to chromosome 8q22.1, spanning at least 50 kb, and is composed of six
introns. The full length of mRNA is 2245-bp, encoding a type III
transmembrane protein with four transmembrane regions. It has been
reported that LAPTM4B is expressed fairly low in normal adult tissue
Figure 1. Schematic diagram showing LAPTM4B promoter and exon 1.Promoter region is depicted as horizontal bar. The closed box is
referred to the exon, and the gray box indicates the 19-bp sequence. Allele *1 contains only one copy of a 19-bp sequence in the first exon,
whereas this sequence is duplicated and tandemly arranged in allele *2. Primers loci are shown as P1 and P2. The nucleotide sequence is
numbered with transcriptional start site as +1. Partial sequences in the first exon from both alleles were shown.
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LAPTM4B is associated with unfavorable biological behaviors and poor
prognosis of many carcinomas, such as hepatocellular carcinoma [10],
gallbladder carcinoma [11], colorectal carcinoma [12], epithelial ovarian
carcinoma [13] and endometrial carcinoma [14]. LAPTM4B could
active PI3K/AKT signaling pathway, which motivates multi-drug
resistance [15] and also involved in drug resistance of melanoma
targeted therapy [16]. LAPTM4B is also crucial for autophagy
maturation that associated with chemotherapy resistance and enhances
tumor survival in metabolic and genotoxic stress [17,18].
There are two alleles of LAPTM4B in the 5′ untranslated region,
named *1 and *2 (GenBank accession numbers AY219176 and
AY219177, respectively) [19]. Allele*1 differs from allele*2 in that it
contains only one copy of a 19-bp sequence in the first exon, whereas
this sequence is duplicated and tandemly arranged in allele*2
(Figure 1). Previous studies showed that the LAPTM4B *2/2-type
allele was significantly associated with the susceptibility of adenocar-
cinoma including lung cancer [20], gastric cancer [21], colorectal
cancers [22], cervical cancer [23] and breast cancer [24], but not in
squamous cell carcinoma such as esophageal carcinoma, rectum
carcinoma [22], and nasopharyngeal carcinoma[25]. However, the
origin of melanocytes is unique: derived from the neural crest cells.
Whether its malignant tumor associated with LAPTM4B gene
polymorphism or not is still unclear. Therefore, a case–control studywas designed to investigate the relationship between LAPTM4B gene
polymorphism and melanoma developing in Chinese patients.
Patients and Methods
Cases
Two hundred twenty Chinese melanoma cases who were
hospitalized in at Beijing Cancer Hospital were collected. The
diagnosis of melanoma was based on the criteria of tumor, node,
metastasis (TNM) classification system formulated by American Joint
Committee on Cancer (AJCC 7th edition, 2010). Final diagnosis of
all patients was confirmed by pathologic investigations. Patient
clinicopathologic features include gender, age, tumor primary lesions,
microscopic depth of tumor invasion (Clark level or Breslow's depth),
ulceration status and gene mutation (C-KIT and BRAF). All patients
consented in writing to participate in the study. This study was
approved by the medical ethics committee of the Beijing Cancer
Hospital and Institute and was conducted according to the
Declaration of Helsinki Principles.
Control Subjects
A total of 617 controls were quoted from the healthy adult data of
Cheng [22] and Wang [25]. The eligible controls were healthy
individuals recruited from employees at the Beijing Cancer Hospital
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Figure 2. The polymorphism was shown by PCR using specific
primers for LAPTM4B.The upper band in each lane was the product
of β-actin that served as the positive internal control. The lower
band depicted the PCR products of LAPTM4B. The lanes 1 to 3 and
5 to 6 were heterozygous genotype *1/2; lanes 4 were homozy-
gous genotype *2/2; lanes 7 to 8 were homozygous genotype *1/1.
Table 1. Distribution of Gender and Age in Case and Control Groups a
Controls Melanoma P
value
(n=617) (n=220)
Gender n (%) 0.011
Male 345 (55.9) 101 (45.9)
Female 272 (44.1) 119 (54.1)
Age n (%) 0.229
≤50 287 (46.5%) 92 (41.8%)
N50 330 (53.5%) 128 (58.2%)
a Analyzed by χ2 test.
Table 2. Distribution of Genotypes and Alleles of LAPTM4B a in Cases and Control Groups
Control b Case OR c P
value
n (%) n (%) (95% CI d)
Genotypes
*1/1 336(54.5) 101(45.9)
*1/2 246(39.9) 102(46.4) 1.396(1.011-1.926) 0.042
*2/2 35(5.7) 17(7.7) 1.619(0.868-3.020) 0.130
Total 617(100.00) 220(100.00)
Alleles
*1 918(74.4) 304(69.1)
*2 316(25.6) 136(30.9) 1.308(1.028-1.663) 0.029
Total 1234(100.00) 440(100.00)
a LAPTM4B, lysosome-associated protein transmembrane 4 beta.
b Data were calculated by unconditional logistic regression adjusted by age and gender status.
c OR, odds ratio.
d CI, confidence interval.
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history of cancer. The blood donors from Beijing Cancer Hospital
were checked for cancer history through their past medical charts.
For the other controls, they were directly asked for their cancer
history. The nurse interviewers explained the aims of this study to the
blood donors, and ask them to read and sign the informed consent
form if they agreed to participate.
Procedures
One milliliter of anticoagulant blood was collected from the vein
and kept in a freezer at −20°C. Genomic DNA was isolated using the
Relaxgene Blood DNA extraction kit (Tiangen Biotech, China)
according manufacturer instructions for polymerase chain reaction
(PCR) assay. The specific primers 5′-GCCGACTAGGG
GACTGGCGGA-3′ (forward) and 5′-CGAGAGCTCC
GAGCTTCTGCC-3′ (reverse) were used for determining the
genotypes of LAPTM4B (Figure 1). Human β-actin was used as
positive internal control, and primers were 5′-TCACCAACTGG
GACGACAT-3 ′ ( forward) , and 5 ′ -AGGTAGTCAGT
CAGGTCCCG-3′(reverse). PCR assay was carried out in a 20 μl
reactionmixture containing 200 to 300 ng of DNA template, 10 μmol of
each primer, 10 μl 2× EASY Tag mix (TransGen Biotech, China) and
7 μl ddH2O. The PCR cycle conditions were 94°C denaturation for
5 min, 37 cycles of 30 sec at 94°C, 30 sec at 60°C and 30 sec at 72°C,
followed by extension at 72°C for 10 min. The PCR products were
analyzed using 3% agarose gel electrophoresis.
Statistical Analysis
The frequency distribution of LAPTM4B genotypes and clinico-
pathological features distributions between groups of cancer cases and
controls were examined by χ2 test or the Fisher’s exact test. Genotypic
frequencies were tested for Hardy-Weinberg equilibrium using the χ2
test. The relationships between melanoma and putative risk factors
were measured using odds ratios (ORs) and the 95% confidence
intervals (CIs) that were derived from unconditional logistical
regression analysis and adjusted by the age and gender. A P value
b0.05 was used as the significance level. All statistical analysis was
carried out with Statistical Product and Service Solutions for
Windows (version 16.0; SPSS).Results
Three different genotypes of 220 melanoma subjects and 617 healthy
controls were identified in PCR products using specific primers for
LAPTM4B. The homozygous *1/1 and *2/2 exhibited a 204-bp
band and a 223-bp band, respectively. The heterozygous genotype *1/
2 has both 204-bp and 223-bp bands. Amplified products for β-actin
existed as a 340-bp band in all positive internal controls (Figure 2).
The LAPTM4B gene polymorphism distribution in both the
control and patients cases were in agreement with expectation on the
basis of the Hardy–Weinberg equilibrium (P values were 0.249 and
0.205, respectively), meaning that the sampling was a good
representative of the population. The distribution of patient age
was normal (P = .317), while the distribution of control was abnormal
(P = .009). The mean (±standard deviation) age of case group was
51.82 (±13.15) years and the median age of control was 52 years.
Gender (P = .011) distribution analysis showed a significant deviation
between the cancer cases and control cases (Table 1).
The distribution of LAPTM4B genotypes was significantly
different between patients and controls. There were more *1/2 and
*2/2 genotypes carriers in the case group than control group, while
*1/1 carriers were more in the control group (Table 2). Adjusted by
gender, unconditional logistic regression analyzes showed that
subjects with LAPTM4B *1/2 and LAPTM4B *2/2 had a 1396-fold
(95% CI = 1.011-1.926) and 1.619-fold (95% CI = 0.868-3.020
higher risk for developing melanoma compared with *1/1 carrier.
The allele frequency was also noticed between patients and healthy
controls (Table 2). In 617 controls, the LAPTM4B*2 allele frequency
was 25.6%, which is significantly lower than that in the cases
(30.9%). Subjects carrying LAPTM4B*2 have a 1.038-fold higher
risk compared with LAPTM4B*1 carriers (95% CI = 1.028-1.663).
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clinicopathological features in cases were analyzed by χ2 test
(Table 2). There was no association between LAPTM4B genotypes
and gender, age, subtype, Clark level of invasion, Breslow thickness,
ulceration, clinical stage, and C-KIT, BRAF gene mutation status. In
this study, AM and MM were the most common subtypes accounted
for 40% and 26.8% of all cases. Clark level of invasion and Breslow
thickness are melanoma measurement system that related the degree
of penetration of melanoma into the skin to the 5-year survival rate
after surgical removal of the melanoma, but they are only suitable for
skin original melanoma. Therefore, 26.8% mucosal melanoma origin
from gastrointestinal tract, vagina, or choroid and 13.2% primary site
unknown cases in this study could not be measured by Clark or
Breslow system. Because the site of the primary lesion was obscured,
detection of melanoma in China was usually late and 79.5% patients
were first diagnosed with lymph node or distant metastasis. Four
common genes mutation were also observed in this study.
The frequencies of C-KIT gene and BRAF gene mutation wereTable 3. Distribution of Various Genotypes of LAPTM4B a in Relation to Clinicopathological and
other Variables in Cases Group
Variable LAPTM4B
genotype
P value LAPTM4B
genotype
P value
*1/1 *1/2 *1/1 *2/2
Gender 0.729 0.627
Male 48 46 48 7
Female 53 56 53 10
Age 0.84 0.914
≤50 43 42 43 7
N50 58 60 58 10
Subtypes 0.943 0.594
AMb 39 41 39 8
MMc 26 28 26 5
CSDd 14 15 14 0
Non-CSD e 7 7 7 1
UP f 15 11 15 3
Clark level of invasion 0.714 0.527
I-II 6 4 6 2
III-V 13 15 13 1
Unknown 82 83 82 14
Breslow thickness 0.144 0.354
≤1.5 mm 1 4 1 1
N1.5 mm 20 12 20 4
Unknown 80 86 80 12
Ulceration 0.317 0.615
Positive 46 38 46 5
Negative 40 45 40 6
Unknown 15 19 15 6
Stage 0.971 0.766
0-II 21 21 21 3
III-IV 80 81 80 14
C-KIT gene aberration 0.146 0.451
Positive 3 7 3 1
Negative 79 69 79 12
Unknown 19 26 19 4
BRAF gene mutation 0.715 0.418
Positive 17 14 17 4
Negative 65 62 65 9
Unknown 19 26 19 4
Analyzed by χ2 test
a LAPTM4B, lysosome-associated protein transmembrane 4 beta.
b AM, acral lentiginous melanoma.
c MM, mucosal melanoma.
d CSD, chronic sun damage.
e Non-CSD, non chronic sun damage.
f UP, unknown primary.6.4% (11/171) and 20.5% (35/171) respectively, but NRAS and
PDGFR genes mutation were not observed (Table 3).
Discussion
In this study, we demonstrated that LAPTM4B gene polymorphism is
one of the susceptible factors of melanoma occurrence in Chinese
population. Compared with the Western countries, the subtypes of
melanoma diagnosed in Chinese patients are different. Previous studies
showed that the two most commonly histology subtypes were AM and
MM, which accounted for 49.4% and 22.6% [6]. For primary lesions
were located in the ultraviolet less contact sites, both the subtypes were
not associated with sunlight exposed. The rapid increasing melanoma
incidence in China may be associated with the lifestyle changes,
although the specific causative factor was still unclear [6]. In this case-
control study, notable higher distribution of LAPTM4B *2 allele and
LAPTM4B *2/2 in the cases group suggests that LAPTM4B *2 be
one of risk factors of melanoma in Chinese patients.
Previous studies showed that LAPTM4B*2 allele was associated with
increased susceptibility of lung cancer [20], gastric cancer [21],
colorectal cancers [22], lymphoma [26], cervical cancer [23] and breast
cancer [24]. The risk of developing these cancers were increased to
1.720, 1.710, 1.512, 1.610, 1.490, and 1.301 fold in individuals
carrying allele *2 in comparison with *1, respectively. In this study, the
LAPTM4B *2 carrier had a 1.457-fold risk of suffering melanoma than
LAPTM4B *1 carrier. Our result was consistent with previous findings.
The two sequence alleles of the LAPTM4B are in homology, with
the exception of a 19-bp difference in the first exon. Shao [8] showed
that LAPTM4B *1 was predicted to encode a 35 kD protein. In allele
*2, the extra 19-bp sequence changed open reading frame of
LAPTM4B gene and made LAPTM4B*2 encode one more protein
isoform, a 40-kD protein, than LAPTM4B*1 (Figure 3). The N-
terminal sequence of LAPTM4B is crucial for its functions, such as
enhancing cell proliferation and signal transduction [19,27]. The
two different protein isoforms may influence physiological activities
and functions of the cancer cell [22]. Moreover, the 19-bp sequence
may act as a cis-acting element to participate in genetic transcrip-
tional regulation.
The gene mutation status of melanoma patients were also observed
in this study. C-KIT and BRAF are the most common mutated genes
in Asian melanomas [28,29]. It has been reported that the incidence
of somatic mutations within the C-KIT, BRAF, NRAS and PDGFRA
genes was 10.1% (58/573), 25.9% (121/468), 7.2% (33/459) and
4.8% (17/352), respectively in Chinese melanoma cases[28,29]. The
frequencies of C-KIT and BRAF mutation were 6.4% (11/171) and
20.5% (35/171) in this study, closing to previous studies. There was
no difference between *2 allele carrier and *1 allele carrier in C-KIT
and BRAF gene mutation, nor in other clinicopathological features.
Therefore, we believed that LAPTM4B was an independent risk
factor in melanoma developing.
To our knowledge, this is the first case-control study focusing on
the possible role of LAPTM4B*2 in melanoma. We concluded that
LAPTM4B*2 is likely contributing to a higher risk of melanoma.
Carrying LAPTM4B *2 is a susceptible factor to melanoma in
Chinese patients.
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(a) Protein coded by LAPTM4B *1
(b) Protein coded by LAPTM4B *2
Figure 3. Comparison of the predicted proteins encoded by LAPTM4B*1 and *2. This schematic diagram shows the initial segments of
first exon in LAPTM4B *1 (a) and LAPTM4B (b). The sequence numbers of the first nucleotide (left) and the final amino acid (right) in each
row are shown, respectively. The nucleotide sequences are numbered with the putative transcription start site as +1. Termination
codons are underlined and marked by symbols #. The 19-bp sequences in both of the alleles are underlined. The mRNA of allele *1 can
only starts translation at nt 157, because of the termination codons at nt 40 and nt 103. However, allele *2 start translation at nt 17,
producing an extra stretch of amino acids (53 aa, gray-shaded letters) at N terminus of LAPTM4B.
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